{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:17:15Z","timestamp":1792451835835,"version":"4.5.0"},"reference-count":94,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1R37CA279822-01"],"award-info":[{"award-number":["1R37CA279822-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010900","name":"Yale Cancer Center","doi-asserted-by":"publisher","award":["P30CA016359"],"award-info":[{"award-number":["P30CA016359"]}],"id":[{"id":"10.13039\/100010900","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["KC190128\/W81XWH-20-1-0882"],"award-info":[{"award-number":["KC190128\/W81XWH-20-1-0882"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["KC220016\/HT9425-23-1-0735"],"award-info":[{"award-number":["KC220016\/HT9425-23-1-0735"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA278980"],"award-info":[{"award-number":["R01CA278980"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U2CCA233195"],"award-info":[{"award-number":["U2CCA233195"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R50CA265182"],"award-info":[{"award-number":["R50CA265182"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunity"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.immuni.2025.10.013","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T15:51:02Z","timestamp":1761925862000},"page":"2814-2829.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Myeloid cells mediate interferon-driven resistance to immunotherapy in advanced renal cell carcinoma"],"prefix":"10.1016","volume":"58","author":[{"given":"Kevin","family":"Bi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soki","family":"Kashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina Y.","family":"Camp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Meli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eddy","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breanna M.","family":"Titchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Labaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad","family":"Bakouny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica M.","family":"Pimenta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihye","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Shannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherin","family":"Xirenayi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Horst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotus","family":"Lum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey J.","family":"Ishizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliezer M.","family":"Van Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.immuni.2025.10.013_bib1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41571-020-00455-z","article-title":"Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma","volume":"18","author":"Braun","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.immuni.2025.10.013_bib2","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s11864-023-01161-5","article-title":"Treatment landscape of renal cell carcinoma","volume":"24","author":"Chen","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.immuni.2025.10.013_bib3","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.immuni.2025.10.013_bib4","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.immuni.2025.10.013_bib5","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.immuni.2025.10.013_bib6","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.immuni.2025.10.013_bib7","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2025.10.013_bib8","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nrclinonc.2017.101","article-title":"The immune contexture in cancer prognosis and treatment","volume":"14","author":"Fridman","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.immuni.2025.10.013_bib9","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1158\/1078-0432.CCR-14-2926","article-title":"Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer","volume":"21","author":"Giraldo","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.immuni.2025.10.013_bib10","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.hoc.2023.05.021","article-title":"Emerging Biomarkers of Response to Systemic Therapies in Metastatic Clear Cell Renal Cell Carcinoma","volume":"37","author":"Labaki","year":"2023","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.immuni.2025.10.013_bib11","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.immuni.2022.03.007","article-title":"The interferon-stimulated gene RIPK1 regulates cancer cell intrinsic and extrinsic resistance to immune checkpoint blockade","volume":"55","author":"Cucolo","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2025.10.013_bib12","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.immuni.2025.10.013_bib13","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2025.10.013_bib14","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.cell.2019.07.019","article-title":"Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade","volume":"178","author":"Benci","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2025.10.013_bib15","first-page":"43","article-title":"Cancer cells resistant to immune checkpoint blockade acquire interferon-associated epigenetic memory to sustain T cell dysfunction","volume":"4","author":"Qiu","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.immuni.2025.10.013_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/science.adf1329","article-title":"Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients","volume":"384","author":"Mathew","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.immuni.2025.10.013_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-32567-8","article-title":"Temporally restricted activation of IFN\u03b2 signaling underlies response to immune checkpoint therapy in mice","volume":"13","author":"Zemek","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.immuni.2025.10.013_bib18","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/s41590-022-01315-x","article-title":"In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer","volume":"23","author":"Dubrot","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2025.10.013_bib19","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.ccell.2023.02.013","article-title":"Mutations in IFN-\u03b3 signaling genes sensitize tumors to immune checkpoint blockade","volume":"41","author":"Song","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.immuni.2025.10.013_bib20","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ccell.2021.02.015","article-title":"Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma","volume":"39","author":"Bi","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.immuni.2025.10.013_bib21","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.ccell.2021.02.013","article-title":"Progressive immune dysfunction with advancing disease stage in renal cell carcinoma","volume":"39","author":"Braun","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.immuni.2025.10.013_bib22","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.ccell.2021.03.007","article-title":"Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy","volume":"39","author":"Krishna","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.immuni.2025.10.013_bib23","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1286-4579(99)00222-1","article-title":"Regulation of HLA class II gene expression: the case for posttranscriptional control levels","volume":"1","author":"Del Pozzo","year":"1999","journal-title":"Microbes Infect."},{"key":"10.1016\/j.immuni.2025.10.013_bib24","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/eji.201646837","article-title":"CD69: from activation marker to metabolic gatekeeper","volume":"47","author":"Cibri\u00e1n","year":"2017","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.immuni.2025.10.013_bib25","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.micinf.2011.10.003","article-title":"XCL1 and XCR1 in the immune system","volume":"14","author":"Lei","year":"2012","journal-title":"Microbes Infect."},{"key":"10.1016\/j.immuni.2025.10.013_bib26","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/s41592-021-01274-5","article-title":"Systematic investigation of cytokine signaling activity at the tissue and single-cell levels","volume":"18","author":"Jiang","year":"2021","journal-title":"Nat. Methods"},{"key":"10.1016\/j.immuni.2025.10.013_bib27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nri3787","article-title":"Type I interferons in infectious disease","volume":"15","author":"McNab","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.immuni.2025.10.013_bib28","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41579-018-0020-5","article-title":"ISG15 in antiviral immunity and beyond","volume":"16","author":"Perng","year":"2018","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.immuni.2025.10.013_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1105309","article-title":"Interferon alpha inducible protein 6 is a negative regulator of innate immune responses by modulating RIG-I activation","volume":"14","author":"Villamayor","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.immuni.2025.10.013_bib30","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nri3344","article-title":"The broad-spectrum antiviral functions of IFIT and IFITM proteins","volume":"13","author":"Diamond","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.immuni.2025.10.013_bib31","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3389\/fcimb.2017.00196","article-title":"The association of OASL and type I interferons in the pathogenesis and survival of intracellular replicating bacterial species","volume":"7","author":"Leisching","year":"2017","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.immuni.2025.10.013_bib32","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.immuni.2025.10.013_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.559","article-title":"Guanylate-binding protein 2 regulates Drp1-mediated mitochondrial fission to suppress breast cancer cell invasion","volume":"8","author":"Zhang","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.immuni.2025.10.013_bib34","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1007\/s00125-023-05991-8","article-title":"IFN\u0263 but not IFN\u03b1 increases recognition of insulin defective ribosomal product-derived antigen to amplify islet autoimmunity","volume":"66","author":"Thomaidou","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.immuni.2025.10.013_bib35","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/gt.2014.54","article-title":"Effects of upregulated indoleamine 2, 3-dioxygenase 1 by interferon \u03b3 gene transfer on interferon \u03b3-mediated antitumor activity","volume":"21","author":"Watcharanurak","year":"2014","journal-title":"Gene Ther."},{"key":"10.1016\/j.immuni.2025.10.013_bib36","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1089\/jir.2009.0082","article-title":"Differential transcriptional responses to interferon-alpha and interferon-gamma in primary human hepatocytes","volume":"30","author":"He","year":"2010","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.immuni.2025.10.013_bib37","doi-asserted-by":"crossref","first-page":"17609","DOI":"10.1073\/pnas.1209724109","article-title":"Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases","volume":"109","author":"Hall","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2025.10.013_bib38","doi-asserted-by":"crossref","first-page":"962","DOI":"10.4049\/jimmunol.1601531","article-title":"Combined single-cell measurement of cytokine mRNA and protein identifies T cells with persistent effector function","volume":"198","author":"Nicolet","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.immuni.2025.10.013_bib39","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1158\/1055-9965.EPI-10-0064","article-title":"Comparison of mRNA and protein measures of cytokines following vaccination with human papillomavirus-16 L1 virus-like particles","volume":"19","author":"Shebl","year":"2010","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.immuni.2025.10.013_bib40","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-019-1324-y","article-title":"TOX is a critical regulator of tumour-specific T cell differentiation","volume":"571","author":"Scott","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2025.10.013_bib41","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","article-title":"TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion","volume":"571","author":"Khan","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2025.10.013_bib42","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s43018-021-00292-8","article-title":"Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer","volume":"3","author":"Liu","year":"2022","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.immuni.2025.10.013_bib43","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1158\/0008-5472.CAN-16-2684","article-title":"CD39 expression defines cell exhaustion in tumor-infiltrating CD8+ T cells","volume":"78","author":"Canale","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.immuni.2025.10.013_bib44","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adg1094","article-title":"TIM-3+ CD8 T cells with a terminally exhausted phenotype retain functional capacity in hematological malignancies","volume":"9","author":"Minnie","year":"2024","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.immuni.2025.10.013_bib45","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.immuni.2019.11.002","article-title":"Proliferating transitory T cells with an effector-like transcriptional signature emerge from PD-1+ stem-like CD8+ T cells during chronic infection","volume":"51","author":"Hudson","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2025.10.013_bib46","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","article-title":"Developmental relationships of four exhausted CD8+ T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms","volume":"52","author":"Beltra","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2025.10.013_bib47","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/s41590-022-01338-4","article-title":"Shared and distinct biological circuits in effector, memory and exhausted CD8+ T cells revealed by temporal single-cell transcriptomics and epigenetics","volume":"23","author":"Giles","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2025.10.013_bib48","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41586-021-03704-y","article-title":"Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma","volume":"596","author":"Oliveira","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2025.10.013_bib49","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/s41590-018-0114-2","article-title":"Tissue-resident memory T cells at the center of immunity to solid tumors","volume":"19","author":"Amsen","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2025.10.013_bib50","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/s41416-023-02202-4","article-title":"Cancer-specific tissue-resident memory T-cells express ZNF683 in colorectal cancer","volume":"128","author":"Kitakaze","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.immuni.2025.10.013_bib51","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41392-023-01522-4","article-title":"Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.immuni.2025.10.013_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1240275","article-title":"Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer","volume":"14","author":"Zeller","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.immuni.2025.10.013_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1421092","article-title":"MHC1\/LILRB1 axis as an innate immune checkpoint for cancer therapy","volume":"15","author":"Hu","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.immuni.2025.10.013_bib54","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10555-020-09932-4","article-title":"Galectin-3: an immune checkpoint target for musculoskeletal tumor patients","volume":"40","author":"Nakajima","year":"2021","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.immuni.2025.10.013_bib55","article-title":"V-Set and immunoglobulin domain containing (VSIG) proteins as emerging immune checkpoint targets for cancer immunotherapy","volume":"13","author":"Zhou","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.immuni.2025.10.013_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.676181","article-title":"The role of V-domain ig suppressor of T cell activation (VISTA) in cancer therapy: Lessons learned and the road ahead","volume":"12","author":"Hosseinkhani","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.immuni.2025.10.013_bib57","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.it.2020.12.008","article-title":"VISTA: A mediator of quiescence and a promising target in cancer immunotherapy","volume":"42","author":"Yuan","year":"2021","journal-title":"Trends Immunol."},{"key":"10.1016\/j.immuni.2025.10.013_bib58","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41586-019-1456-0","article-title":"CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy","volume":"572","author":"Barkal","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2025.10.013_bib59","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00262-023-03606-0","article-title":"Targeting CD24\/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions","volume":"73","author":"Li","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.immuni.2025.10.013_bib60","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","volume":"24","author":"McDermott","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2025.10.013_bib61","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.immuni.2025.10.013_bib62","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.ccell.2020.10.011","article-title":"Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade","volume":"38","author":"Motzer","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.immuni.2025.10.013_bib63","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.immuni.2025.10.013_bib64","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1038\/s41591-020-1044-8","article-title":"Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial","volume":"26","author":"Motzer","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2025.10.013_bib65","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","article-title":"Determining cell type abundance and expression from bulk tissues with digital cytometry","volume":"37","author":"Newman","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.immuni.2025.10.013_bib66","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1158\/2326-6066.CIR-18-0277","article-title":"T cell-inflamed versus non-T cell-inflamed tumors: A conceptual framework for cancer immunotherapy drug development and combination therapy selection","volume":"6","author":"Trujillo","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.immuni.2025.10.013_bib67","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1038\/s41591-024-02978-9","article-title":"A spatial architecture-embedding HLA signature to predict clinical response to immunotherapy in renal cell carcinoma","volume":"30","author":"Kinget","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2025.10.013_bib68","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1126\/science.ade2292","article-title":"CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers","volume":"381","author":"Bill","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.immuni.2025.10.013_bib69","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.immuni.2025.10.013_bib70","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/2159-8290.CD-14-0863","article-title":"The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints","volume":"5","author":"Llosa","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.immuni.2025.10.013_bib71","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2025.10.013_bib72","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2025.10.013_bib73","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.immuni.2025.10.013_bib74","doi-asserted-by":"crossref","first-page":"5456","DOI":"10.1158\/1078-0432.CCR-20-1303","article-title":"PD-L1 protein expression on both tumor cells and macrophages are associated with response to neoadjuvant durvalumab with chemotherapy in triple-negative breast cancer","volume":"26","author":"Ahmed","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.immuni.2025.10.013_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100745","article-title":"Choosing the right animal model for renal cancer research","volume":"13","author":"Sobczuk","year":"2020","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.immuni.2025.10.013_bib76","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1158\/2159-8290.CD-21-0925","article-title":"A targetable myeloid inflammatory state governs disease recurrence in clear-cell renal cell carcinoma","volume":"12","author":"Rappold","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.immuni.2025.10.013_bib77","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2408549121","article-title":"Toward a CRISPR-based mouse model of Vhl-deficient clear cell kidney cancer: Initial experience and lessons learned","volume":"121","author":"Stransky","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2025.10.013_bib78","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.trecan.2022.09.003","article-title":"How cancer cells make and respond to interferon-I","volume":"9","author":"Cheon","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.immuni.2025.10.013_bib80","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/s41592-023-01943-7","article-title":"Unsupervised removal of systematic background noise from droplet-based single-cell experiments using CellBender","volume":"20","author":"Fleming","year":"2023","journal-title":"Nat. Methods"},{"key":"10.1016\/j.immuni.2025.10.013_bib81","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cels.2018.11.005","article-title":"Scrublet: Computational identification of cell Doublets in Single-cell transcriptomic data","volume":"8","author":"Wolock","year":"2019","journal-title":"Cell Syst."},{"key":"10.1016\/j.immuni.2025.10.013_bib82","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","article-title":"Integrated analysis of multimodal single-cell data","volume":"184","author":"Hao","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2025.10.013_bib83","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","article-title":"Fast, sensitive and accurate integration of single-cell data with Harmony","volume":"16","author":"Korsunsky","year":"2019","journal-title":"Nat. Methods"},{"key":"10.1016\/j.immuni.2025.10.013_bib85","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1093\/bioinformatics\/btac161","article-title":"hacksig: a unified and tidy R framework to easily compute gene expression signature scores","volume":"38","author":"Carenzo","year":"2022","journal-title":"Bioinformatics"},{"key":"10.1016\/j.immuni.2025.10.013_bib86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v082.i13","article-title":"LmerTest package: Tests in linear mixed effects models","volume":"82","author":"Kuznetsova","year":"2017","journal-title":"J. Stat. Softw."},{"key":"10.1016\/j.immuni.2025.10.013_bib87","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.immuni.2025.10.013_bib88","doi-asserted-by":"crossref","first-page":"10","DOI":"10.14806\/ej.17.1.200","article-title":"Cutadapt removes adapter sequences from high-throughput sequencing reads","volume":"17","author":"Martin","year":"2011","journal-title":"EMBnet J."},{"key":"10.1016\/j.immuni.2025.10.013_bib89","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/1471-2105-12-323","article-title":"RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome","volume":"12","author":"Li","year":"2011","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.immuni.2025.10.013_bib90","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1093\/bioinformatics\/btab135","article-title":"RNA-SeQC 2: efficient RNA-seq quality control and quantification for large cohorts","volume":"37","author":"Graubert","year":"2021","journal-title":"Bioinformatics"},{"key":"10.1016\/j.immuni.2025.10.013_bib92","doi-asserted-by":"crossref","first-page":"R41","DOI":"10.1186\/gb-2011-12-4-r41","article-title":"GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers","volume":"12","author":"Mermel","year":"2011","journal-title":"Genome Biol."},{"key":"10.1016\/j.immuni.2025.10.013_bib79","doi-asserted-by":"crossref","first-page":"D766","DOI":"10.1093\/nar\/gky955","article-title":"GENCODE reference annotation for the human and mouse genomes","volume":"47","author":"Frankish","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.immuni.2025.10.013_bib84","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1000217","article-title":"Inferring pathway activity toward precise disease classification","volume":"4","author":"Lee","year":"2008","journal-title":"PLOS Comput. Biol."},{"key":"10.1016\/j.immuni.2025.10.013_bib91","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/s41591-020-0839-y","article-title":"Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma","volume":"26","author":"Braun","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2025.10.013_bib93","article-title":"Generating DE Novo antigen-specific human T cell receptors by Retroviral transduction of centric hemichain","volume":"116","author":"Guo","year":"2016","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.immuni.2025.10.013_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.100998","article-title":"Cytotoxic T lymphocytes regenerated from iPS cells have therapeutic efficacy in a patient-derived xenograft solid tumor model","volume":"23","author":"Kashima","year":"2020","journal-title":"iScience"}],"container-title":["Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1074761325004686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1074761325004686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T05:12:24Z","timestamp":1773810744000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1074761325004686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":94,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1074761325004686"],"URL":"https:\/\/doi.org\/10.1016\/j.immuni.2025.10.013","relation":{},"ISSN":["1074-7613"],"issn-type":[{"value":"1074-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myeloid cells mediate interferon-driven resistance to immunotherapy in advanced renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Immunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.immuni.2025.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}